Genmab — Februar 2018
-
-
BMY har lavet en del buzz omkring lung cancer behandling og deres checkmate studier. Er der nogen der har kigget nærmere på det. De referater jeg lige har skimmet taler om gennembrud og forståelse af hvordan man behandler lung cancer og måske flere typer cancer.
-
@Solsen jeg har ikke dykket ned i data, men her er en kritisk vinkel på BMY checkmate 227 og anvendelsen af TMB (tumor mutation burden) https://www.marketwatch.com/story/bristol-myers-touts-lung-cancer-breakthrough-but-critics-cry-foul-2018-02-05?siteid=yhoof2&yptr=yahoo
-
TMB diskuteres yderligere i BMY Earnings Call Transcript, både i starten og under Q&A https://seekingalpha.com/article/4143270-bristol-myers-squibbs-bmy-giovanni-caforio-q4-2017-results-earnings-call-transcript?part=single
-
Mere om TMB, mulig markør for effektivitet af PD-1 / PD-L1 midler https://www.ncbi.nlm.nih.gov/pubmed/28835386
https://www.genengnews.com/gen-exclusives/the-promise-of-tumor-mutational-burden-for-cancer-immunotherapy/77900833 -
God morgen.
-
-
Stock Market Futures - Investing.com
Discover real-time streaming rates in our comprehensive stock futures table, covering global futures markets, including US stock futures.
Investing.com (www.investing.com)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind